Shanghai Haixin Group Co Ltd A Asset Resilience Ratio
Shanghai Haixin Group Co Ltd A asset resilience ratio. Shanghai Haixin Group Co Ltd A (600851) has an Asset Resilience Ratio of 13.88% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Haixin Group Co Ltd A defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Haixin Group Co Ltd A (1994–2025)
Asset resilience ratio of Shanghai Haixin Group Co Ltd A from 1994 to 2025. This chart shows how Shanghai Haixin Group Co Ltd A's Asset Resilience Ratio has changed over time. Read 600851 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haixin Group Co Ltd A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600851 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥866.47 Million | 13.88% |
| Total Liquid Assets | CN¥866.47 Million | 13.88% |
Asset Resilience Insights
- Moderate Liquidity: Shanghai Haixin Group Co Ltd A has 13.88% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haixin Group Co Ltd A Industry Peers by Asset Resilience Ratio
Compare Shanghai Haixin Group Co Ltd A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Mytilineos S.A
AT:MYTIL |
Conglomerates | 0.38% |
|
Shelly Group SE
XETRA:SLYG |
Conglomerates | 0.08% |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV |
Conglomerates | 3.20% |
|
Kolon Corp
KO:002025 |
Conglomerates | 0.77% |
|
Webac Holding AG
F:RKB |
Conglomerates | 0.22% |
|
Pampa Energia SA
BA:PAMP |
Conglomerates | 3.90% |
|
Cresud SA
BA:CRES |
Conglomerates | 4.52% |
|
Ledesma SAAI
BA:LEDE |
Conglomerates | 1.01% |
Shanghai Haixin Group Co Ltd A Asset Resilience Ratio by Year (1994–2025)
Shanghai Haixin Group Co Ltd A asset resilience ratio by year from 1994 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Haixin Group Co Ltd A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.25% | CN¥773.93 Million ≈ $113.25 Million |
CN¥5.84 Billion ≈ $854.88 Million |
+7.99pp |
| 2024-12-31 | 5.26% | CN¥280.19 Million ≈ $41.00 Million |
CN¥5.33 Billion ≈ $780.15 Million |
+1.18pp |
| 2023-12-31 | 4.07% | CN¥200.00 Million ≈ $29.27 Million |
CN¥4.91 Billion ≈ $718.58 Million |
-1.91pp |
| 2022-12-31 | 5.98% | CN¥295.03 Million ≈ $43.17 Million |
CN¥4.93 Billion ≈ $721.42 Million |
+1.47pp |
| 2021-12-31 | 4.52% | CN¥240.50 Million ≈ $35.19 Million |
CN¥5.33 Billion ≈ $779.31 Million |
+2.26pp |
| 2020-12-31 | 2.26% | CN¥127.01 Million ≈ $18.59 Million |
CN¥5.63 Billion ≈ $823.12 Million |
+1.97pp |
| 2019-12-31 | 0.28% | CN¥14.65 Million ≈ $2.14 Million |
CN¥5.16 Billion ≈ $754.85 Million |
-2.41pp |
| 2018-12-31 | 2.69% | CN¥121.47 Million ≈ $17.78 Million |
CN¥4.51 Billion ≈ $659.87 Million |
+2.45pp |
| 2017-12-31 | 0.25% | CN¥12.06 Million ≈ $1.77 Million |
CN¥4.89 Billion ≈ $715.87 Million |
-0.42pp |
| 2015-12-31 | 0.66% | CN¥40.02 Million ≈ $5.86 Million |
CN¥6.04 Billion ≈ $884.48 Million |
-0.71pp |
| 2014-12-31 | 1.37% | CN¥99.64 Million ≈ $14.58 Million |
CN¥7.27 Billion ≈ $1.06 Billion |
+1.14pp |
| 2013-12-31 | 0.24% | CN¥10.36 Million ≈ $1.52 Million |
CN¥4.39 Billion ≈ $642.20 Million |
+0.02pp |
| 2012-12-31 | 0.22% | CN¥9.49 Million ≈ $1.39 Million |
CN¥4.35 Billion ≈ $636.41 Million |
-0.07pp |
| 2011-12-31 | 0.29% | CN¥11.52 Million ≈ $1.69 Million |
CN¥3.97 Billion ≈ $580.40 Million |
+0.20pp |
| 2010-12-31 | 0.09% | CN¥4.43 Million ≈ $648.09K |
CN¥4.67 Billion ≈ $683.29 Million |
-0.07pp |
| 2009-12-31 | 0.17% | CN¥10.28 Million ≈ $1.50 Million |
CN¥6.18 Billion ≈ $904.51 Million |
+0.08pp |
| 2008-12-31 | 0.08% | CN¥3.52 Million ≈ $515.00K |
CN¥4.19 Billion ≈ $613.39 Million |
+0.07pp |
| 2007-12-31 | 0.02% | CN¥1.44 Million ≈ $210.97K |
CN¥8.92 Billion ≈ $1.31 Billion |
+0.01pp |
| 2006-12-31 | 0.01% | CN¥300.00K ≈ $43.90K |
CN¥3.93 Billion ≈ $574.84 Million |
-0.02pp |
| 2005-12-31 | 0.03% | CN¥1.03 Million ≈ $151.25K |
CN¥3.81 Billion ≈ $557.92 Million |
-0.15pp |
| 2004-12-31 | 0.18% | CN¥6.68 Million ≈ $977.88K |
CN¥3.82 Billion ≈ $558.60 Million |
+0.16pp |
| 2003-12-31 | 0.02% | CN¥620.00K ≈ $90.73K |
CN¥3.57 Billion ≈ $522.51 Million |
+0.01pp |
| 2002-12-31 | 0.00% | CN¥120.00K ≈ $17.56K |
CN¥3.30 Billion ≈ $482.37 Million |
-0.56pp |
| 2001-12-31 | 0.56% | CN¥16.90 Million ≈ $2.47 Million |
CN¥3.02 Billion ≈ $441.97 Million |
-8.97pp |
| 2000-12-31 | 9.53% | CN¥254.47 Million ≈ $37.24 Million |
CN¥2.67 Billion ≈ $390.71 Million |
+8.08pp |
| 1997-12-31 | 1.45% | CN¥21.49 Million ≈ $3.15 Million |
CN¥1.48 Billion ≈ $217.03 Million |
+0.72pp |
| 1996-12-31 | 0.73% | CN¥7.72 Million ≈ $1.13 Million |
CN¥1.06 Billion ≈ $155.69 Million |
-2.00pp |
| 1995-12-31 | 2.73% | CN¥20.65 Million ≈ $3.02 Million |
CN¥757.31 Million ≈ $110.82 Million |
-1.76pp |
| 1994-12-31 | 4.49% | CN¥24.08 Million ≈ $3.52 Million |
CN¥536.72 Million ≈ $78.54 Million |
-- |
About Shanghai Haixin Group Co Ltd A
Shanghai Haixin Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China and internationally. It is also involved in leasing of industrial park properties, financial investment and commodity trading, as well as production and sales of chemical drugs through its sales platform or local distributors; and research and development, production, and sales of plush fabrics… Read more